1. Pink Sheet
  2. >>Product Reviews

US FDA’s 2022 Novel Agent Actions Suggest Acceleration In Use Of Complete Response Letters

 
• By Bridget Silverman

COVID does not appear to be a driving factor, and letters are split almost equally between clinical and quality concerns.

FDA Complete response stamp holder
US FDA has been using its "complete response" stamp more frequently. • Source: Nielsen Hobbs; the Pink Sheet | Alamy image

The year 2022 has seen a dramatic escalation in the rate of complete response letters to approvals of novel agents, even against the backdrop of increasing CRL numbers in the past several years, a Pink Sheet analysis of our US FDA Performance Tracker data shows.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Complete Response Letters

More from Product Reviews

US FDA User Fee Collection Safe In Preliminary Trump 2026 Budget Plan

 
• By Cathy Kelly

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include four new products, one of which is Tivdak, Pfizer/Genmab’s treatment for previously treated recurrent or metastatic cervical cancer.

US CDC Panel Recommends Some 50-59 Year-Olds For RSV Vaccination

 
• By Bridget Silverman

All RSV vaccines with US FDA approval for high-risk younger adult patients will be incorporated in US CDC’s Advisory Committee for Immunization Practices recommendations. Merck’s infant RSV antibody is on track for a June vote